On June 24, 2016 Takeda Pharmaceutical Company Limited (TSE: 4502) reported revisions on an existing collaboration agreement, under which Takeda had rights to develop and commercialize multiple molecules / products from Amgen’s pipeline for the Japanese market (Press release, Takeda, JUN 24, 2016, View Source [SID:1234513534]). By the revisions, such rights for molecules / products including AMG403 and AMG386 will be returned to Amgen, effective immediately. Schedule your 30 min Free 1stOncology Demo! Takeda and Amgen will continue to collaborate on the development and commercialization of remaining molecules / products for the Japanese market, including Vectibix (panitumumab), a leading treatment for unresectable advanced or recurrent colorectal cancer.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Through our work with Amgen, we have successfully delivered Vectibix to the Japanese patients facing a challenging diagnosis while continuing to build our scientific understanding of novel treatment pathways," said Phil Rowlands, Interim Head, Oncology Therapeutic Area Unit, Takeda. "We look forward to continuing our scientific discovery and to building a portfolio of innovative medicines through our ongoing collaboration with Amgen."
Takeda will work with Amgen to ensure a smooth transition of these molecules / products, and will cooperate with Amgen to ensure patients who receives study drug that include any of such molecules / products will receive appropriate therapies in Japan.
Takeda Revises Collaboration Agreement with Amgen, Returning the Development and Commercialization Rights of Molecules / Products for Japan
On June 24, 2016 Takeda Pharmaceutical Company Limited (TSE: 4502) reported revisions on an existing collaboration agreement, under which Takeda had rights to develop and commercialize multiple molecules / products from Amgen’s pipeline for the Japanese market (Press release, Takeda, JUN 24, 2016, View Source [SID:1234513534]). By the revisions, such rights for molecules / products including AMG403 and AMG386 will be returned to Amgen, effective immediately.
Takeda and Amgen will continue to collaborate on the development and commercialization of remaining molecules / products for the Japanese market, including Vectibix (panitumumab), a leading treatment for unresectable advanced or recurrent colorectal cancer.
“Through our work with Amgen, we have successfully delivered Vectibix to the Japanese patients facing a challenging diagnosis while continuing to build our scientific understanding of novel treatment pathways,” said Phil Rowlands, Interim Head, Oncology Therapeutic Area Unit, Takeda. “We look forward to continuing our scientific discovery and to building a portfolio of innovative medicines through our ongoing collaboration with Amgen.”
Takeda will work with Amgen to ensure a smooth transition of these molecules / products, and will cooperate with Amgen to ensure patients who receives study drug that include any of such molecules / products will receive appropriate therapies in Japan.